| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|
Phase N/A 1
2 3 4 Trials | | 0 | 12345678910 |
|---|
| | | | |
|---|
| | | | |
|---|
| | | | |
|---|
| NI-071 (infliximab biosimilar) / Sanofi, Nichi-Iko, Aprogen, Elea Labs | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Alymsys (bevacizumab-maly) / Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi-Iko, Stada | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Nepexto (etanercept biosimilar) / Biocon, Lupin, YL Biologics, Nichi-Iko, Viatris | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
|
